Dallas, TX -- (ReleaseWire) -- 04/17/2014 -- COPD Drug Market Opportunity & Clinical Pipeline Analysis report says close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the variable airflow and airway hyper-responsiveness to many intrinsic, genetic and environmental stimuli. These disorders have become one of the major reasons for disability and death. The prevalence and incidence of this disease is increasing worldwide. Complete report is available at http://www.reportsnreports.com/reports/280894-copd-drug-market-opportunity-clinical-pipeline-analysis.html .
Bronchodilators and polypharmacy dominates the treatment for this disease. It is expected that by 2020, COPD would account for more than 6 Million deaths across the globe annually. Inspite of significant investments in the development of novel agents to treat the disease, the COPD therapy area is generally dominated by inhaled bronchodilator therapies which only relieve symptoms, but do not completely cure the disease. There exist many opportunities for a disease-modifying therapy. However, the development of new COPD therapies is increasingly focusing on therapies which combine two bronchodilators into one inhaler.
The global market for COPD has been estimated to be close to US$ 12 billion in 2013. With a high number of new and more efficient and convenient drugs crowding the market, it is expected that this market would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018. Some of the drugs which are major contributors to this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium. By 2018, it is expected that the combinations of LABA/LAMA would the leading drugs driving sales in the COPD therapy market and by 2021, these drugs would account for more than 25% of the market share. While in 2013, close to 50% of the global market was accounted by the US, with the other regions together accounting for 50%. However, it is expected that by 2018, the share of the USA would reduce marginally to 45%, while the lost share of this region would be taken over by the Asian region.
"COPD Drug Market Opportunity & Clinical Pipeline Analysis" Report Highlights:
- COPD Drug Market Overview
- COPD Patient Base: Global, US & Europe
- FDA & EMA Guidelines on Clinical Investigation of COPD Drugs
- COPD Drug Clinical Pipeline by Phase & Country
- COPD Drug in Development Phase: 174
- Majority of COPD Drugs in Preclinical Phase: 72
- Marketed COPD Drugs: 36
- Discontinued & Suspended COPD Drug Profiles
Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=280894 .
Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 400,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your research requirements or email the details on email@example.com and we would be happy to help you find the business intelligence that you need.